Caregiver shortages limit access to transplant, CAR T, and bispecific therapies, and no system offers replacement support, says Duke's Thomas LeBlanc, MD, MA.
Thomas LeBlanc, MD, MA
Advertisement
Thomas LeBlanc, MD, MA, is the chief patient experience and safety officer at Duke Cancer Institute.
Articles by Thomas LeBlanc, MD, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
An Odyssey of Symptoms, Setbacks, Treatments, and a Cure With CAR T-Cell Therapy
5